When to perform positron emission tomography/computed tomography or radionuclide bone scan in patients with recently diagnosed prostate cancer

Cancer Management and Research

Volumn 5, Issue 1, 2013, Pages 123-131

  Caldarella, Carmelo ^a   Treglia, Giorgio ^b   Giordano, Alessandro ^a   Giovanella, Luca ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

Author keywords

Bisphosphonates; Bone metastases; Positron emission tomography; Prostate cancer

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CHOLINE C 11; CHOLINE DERIVATIVE; FLUOROCHOLINE F 18; FLUORODEOXYGLUCOSE F 18; HYDROXYMETHYLENE BISPHOSPHONATE TC 99M; METHYLENE BISPHOSPHONATE TC 99M; RADIOPHARMACEUTICAL AGENT; SODIUM FLUORIDE F 18; UNCLASSIFIED DRUG;

BONE METASTASIS; BONE SCINTISCANNING; BONE TURNOVER; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RISK; CLINICAL PRACTICE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; DRUG UPTAKE; EARLY DIAGNOSIS; HEALTH CARE ACCESS; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; ISOTOPE LABELING; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYSTEMIC THERAPY; TREATMENT INDICATION;

EID: 84879325948     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S34685     Document Type: Review

References (60)

1. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol. 2012;30(2):195-200.
2. Crawford ED. Epidemiology of prostate cancer. Urology. 2003; 62(6 Suppl 1):3-12.
3. Punnen S, Cooperberg MR. The epidemiology of high-risk prostate cancer. Curr Opin Urol. Epub April 24, 2013.
4. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61(1):195-202.
5. Ohmori K, Matsui H, Yasuda T, et al. Evaluation of the prognosis of cancer patients with metastatic bone tumors based on serial bone scintigrams. Jpn J Clin Oncol. 1997;27(4):263-267.
6. Sabbatini P, Larson SM, Kremer A, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol. 1999;17(3):948-957.
7. Rigaud J, Tiguert R, Le Normand L, et al. Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy. J Urol. 2002;168(4 Pt 1): 1423-1426.
8. Cheng HH, Lin DW, Yu EY. Advanced clinical states in prostate cancer. Urol Clin North Am. 2012;39(4):561-571.
9. Tanaka N, Fujimoto K, Shinkai T, et al. Bone scan can be spared in asymptomatic prostate cancer patients with PSA of,20 ng/mL and Gleason score of,6 at the initial stage of diagnosis. Jpn J Clin Oncol. 2011;41(10):1209-1213.
10. Moslehi M, Cheki M, Salehi-Marzijarani M, Amuchastegui T, Gholamrezanezhad A. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer. Rev Esp Med Nucl Imagen Mol. Epub March 8, 2013.
11. Long MA, Husband JE. Features of unusual metastases from prostate cancer. Br J Radiol. 1999;72(862):933-941.
12. Reigman HI, Stokkel MP. Peripheral bone metastases in prostate cancer: a rare localization at initial presentation. Clin Nucl Med. 2004;29(5):335-336.
13. Tombal B, Lecouvet F. Modern detection of prostate cancer's bone metastasis: is the bone scan era over? Adv Urol. 2012;2012:893193.
14. Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V. Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol. 2013;24(5):1141-1162.
15. Mari Aparici C, Seo Y. Functional imaging for prostate cancer: therapeutic implications. Semin Nucl Med. 2012;42(5):328-342.
16. Khokher MA, Dandona P. Diphosphonates inhibit human osteoblast secretion and proliferation. Metabolism. 1989;38(2):184-187.
17. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med. 2006;47(2):287-297.
18. Langsteger W, Haim S, Knauer M, et al. Imaging of bone metastases in prostate cancer: an update. Q J Nucl Med Mol Imaging. 2012;56(5): 447-458.
19. Damle NA, Bal C, Bandopadhyaya GP, et al. The role of (18)F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and (99m)Tc-MDP bone scan. Jpn J Radiol. 2013;31(4):262-269.
20. Withofs N, Grayet B, Tancredi T, et al. 18F-fluoride PET/CT for assessing bone involvement in prostate and breast cancers. Nucl Med Commun. 2011;32(3):168-176.
21. Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 2005;202(3):654-662.
22. Smith TA. Mammalian hexokinases and their abnormal expression in cancer. Br J Biomed Sci. 2000;57(2):170-178.
23. Jadvar H, Xiankui L, Shahinian A, et al. Glucose metabolism of human prostate cancer mouse xenografts. Mol Imaging. 2005;4(2):91-97.
24. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology. 1996;199(3):751-756.
25. Yeh SD, Imbriaco M, Larson SM, et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl Med Biol. 1996;23(6):693-697.
26. Morris MJ, Akhurst T, Osman I, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology. 2002;59(6):913-918.
27. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 2001;61(9):3599-3603.
28. Sutinen E, Nurmi M, Roivainen A, et al. Kinetics of [(11)C]choline uptake in prostate cancer: a PET study. Eur J Nucl Med Mol Imaging. 2004;31(3):317-324.
29. Bouchelouche K, Tagawa ST, Goldsmith SJ, Turkbey B, Capala J, Choyke P. PET/CT imaging and radioimmunotherapy of prostate cancer. Semin Nucl Med. 2011;41(1):29-44.
30. Evangelista L, Zattoni F, Guttilla A, et al. Choline PET or PET/CT and biochemical relapse of prostate cancer: a systematic review and meta-analysis. Clin Nucl Med. 2013;38(5):305-314.
31. Beheshti M, Vali R, Waldenberger P, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging. 2008; 35(10):1766-1774.
32. Beheshti M, Vali R, Waldenberger P, et al. The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT. Mol Imaging Biol. 2010;12(1):98-107.
33. Beheshti M, Imamovic L, Broinger G, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology. 2010;254(3):925-933.
34. Tuncel M, Souvatzoglou M, Herrmann K, et al. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Biol. 2008;35(6):689-695.
35. Umbehr MH, Müntener M, Hany T, Sulser T, Bachmann LM. The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol. Epub April 19, 2013.
36. Al-Tamimi A, Tan AE, Kwong SY, Sam CC, Chong A, Tan CH. False-negative bone scan and choline PET/CT study in a case of prostate cancer: the pitfall of the small cell prostate carcinoma variant. World J Nucl Med. 2012;11(2):75-78.
37. Giovacchini G, Gajate AM, Messa C, Fazio F. Increased C-11 choline uptake in pagetic bone in a patient with coexisting skeletal metastases from prostate cancer. Clin Nucl Med. 2008;33(11):797-798.
38. Schirrmeister H, Guhlmann A, Elsner K, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med. 1999;40(10):1623-1629.
39. Hetzel M, Arslandemir C, König HH, et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res. 2003;18(12): 2206-2214.
40. Krüger S, Buck AK, Mottaghy FM, et al. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2009;36(11):1807-1812.
41. Li Y, Schiepers C, Lake R, Dadparvar S, Berenji GR. Clinical utility of (18)F-fluoride PET/CT in benign and malignant bone diseases. Bone. 2012;50(1):128-139.
42. Tateishi U, Morita S, Taguri M, et al. A meta-analysis of (18)F-fluoride positron emission tomography for assessment of metastatic bone tumor. Ann Nucl Med. 2010;24(7):523-531.
43. Langsteger W, Balogova S, Huchet V, et al. Fluorocholine (18F) and sodium fluoride (18F) PET/CT in the detection of prostate cancer: prospective comparison of diagnostic performance determined by masked reading. Q J Nucl Med Mol Imaging. 2011;55(4):448-457.
44. [No authors listed]. Prostate-specific antigen (PSA) best practice policy. American Urological Association (AUA). Oncology (Williston Park). 2000;14(2):267-272, 277-278, 280 passim.
45. American Urological Association. Prostate-specific antigen (PSA) best practice statement: 2009 update. Available from: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf. Accessed April 23, 2013.
46. Greene KL, Albertsen PC, Babaian RJ, et al. Prostate specific antigen best practice statement: 2009 update. J Urol. 2013;189(Suppl 1): S2-S11.
47. Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol. 2004;171(6 Pt 1): 2122-2127.
48. De Nunzio C, Leonardo C, Franco G, et al. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of a novel risk stratification tool. World J Urol. 2013;31(2):365-369.
49. Choi WW, Williams SB, Gu X, Lipsitz SR, Nguyen PL, Hu JC. Overuse of imaging for staging low risk prostate cancer. J Urol. 2011;185(5): 1645-1649.
50. Prasad SM, Gu X, Lipsitz SR, Nguyen PL, Hu JC. Inappropriate utilization of radiographic imaging in men with newly diagnosed prostate cancer in the United States. Cancer. 2012;118(5):1260-1267.
51. Garcia G Jr, Riera E, Valls E, et al. Bone metastases from prostate cancer: 18F-fluoride PET/CT in a patient with discordant bone scintigraphy and 11C-choline PET/CT. Clin Nucl Med. 2013;38(2):120-124.
52. Fuccio C, Castellucci P, Schiavina R, et al. Role of 11C-choline PET/CT in the re-staging of prostate cancer patients with biochemical relapse and negative results at bone scintigraphy. Eur J Radiol. 2012;81(8): e893-e896.
53. Picchio M, Spinapolice EG, Fallanca F, et al. [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging. 2012;39(1):13-26.
54. Fuccio C, Castellucci P, Schiavina R, et al. Role of 11C-choline PET/CT in the restaging of prostate cancer patients showing a single lesion on bone scintigraphy. Ann Nucl Med. 2010;24(6):485-492.
55. Balogova S, Huchet V, Egrot C, et al. Effect of erythropoietin on bone marrow uptake of 18F-fluorocholine in prostate cancer: comparison with 18F-fluoride uptake. Clin Nucl Med. 2013;38(3):200-202.
56. Picchio M, Castellucci P. Clinical indications of C-choline PET/CT in prostate cancer patients with biochemical relapse. Theranostics. 2012;2(3):313-317.
57. Scattoni V, Picchio M, Suardi N, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol. 2007;52(2): 423-429.
58. Jadvar H, Desai B, Ji L, et al. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012;37(7): 637-643.
59. Mosavi F, Johansson S, Sandberg DT, et al. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am J Roentgenol. 2012;199(5):1114-1120.
60. Jadvar H. Imaging evaluation of prostate cancer with (18)F-fluorodeoxyglucose PET/CT: utility and limitations. Eur J Nucl Med Mol Imaging. Epub February 22, 2013.